Deutsche Bank set a €90.00 ($104.65) price target on Sanofi (EPA:SAN) in a research report report published on Monday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Several other research analysts have also weighed in on the stock. Jefferies Financial Group reaffirmed a buy rating on shares of Linde in a research note on Friday, June 21st. UBS Group reaffirmed a hold rating and set a $7.80 target price on shares of Deutsche Bank in a research note on Friday, April 26th. Goldman Sachs Group set a $13.00 target price on shares of Ford Motor and gave the stock a buy rating in a research note on Thursday, June 13th. JPMorgan Chase & Co. raised shares of ROYAL MAIL PLC/ADR from an underweight rating to a neutral rating in a research note on Monday, June 3rd. Finally, HSBC reissued a buy rating and issued a price objective on shares of Deutsche Telekom in a research note on Tuesday, June 11th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of €85.47 ($99.38).

Shares of SAN stock opened at €74.39 ($86.50) on Monday. The stock’s 50-day moving average is €76.08. Sanofi has a 1-year low of €63.09 ($73.36) and a 1-year high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: What Does a Sell-Side Analyst Rating Mean?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.